COX-2 inhibitors, including aspirin, can decrease the production of PGE2, which is associated with a lower risk of breast cancer progression as COX-2 is constitutively expressed at high levels in breast cancer cells [168]. This evidence concerns the gene PTGS2 and breast carcinoma.